CUR - Neuralstem, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
1.37
-0.05 (-3.52%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.42
Open1.45
Bid1.31 x 800
Ask1.45 x 1000
Day's Range1.35 - 1.53
52 Week Range0.22 - 6.60
Volume876,582
Avg. Volume703,300
Market Cap16.6M
Beta0.71
PE Ratio (TTM)-0.62
EPS (TTM)-2.22
Earnings DateNov 6, 2017 - Nov 10, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est26.00
Trade prices are not sourced from all markets
  • One Thing To Consider Before Buying Neuralstem Inc (CUR)
    Simply Wall St.7 days ago

    One Thing To Consider Before Buying Neuralstem Inc (CUR)

    For Neuralstem Inc’s (NASDAQ:CUR) shareholders, and also potential investors in the stock, understanding how the stock’s risk and return characteristics can impact your portfolio is important. Every stock in theRead More...

  • ACCESSWIRE27 days ago

    Neuralstem: Stock falls in July on Phase II Miss, Gets 2 New Patents for Neural Stem Cells

    NEW YORK, NY / ACCESSWIRE / September 27, 2017 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive ...

  • GlobeNewswire29 days ago

    Neuralstem Announces the Appointment of Two New Members to the Board of Directors

    GERMANTOWN, Md., Sept. 25, 2017-- Neuralstem, Inc., a biopharmaceutical company developing novel treatments for nervous system diseases, today announced that Zhang Zhuo and Cristina Csimma, PharmD, MHP, ...

  • Capital Cubelast month

    ETFs with exposure to Neuralstem, Inc. : September 22, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Neuralstem, Inc. Here are 5 ETFs with the largest exposure to CUR-US. Comparing the performance and risk of Neuralstem, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Capital Cubelast month

    ETFs with exposure to Neuralstem, Inc. : September 12, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Neuralstem, Inc. Here are 5 ETFs with the largest exposure to CUR-US. Comparing the performance and risk of Neuralstem, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • TheStreet.com2 months ago

    Intra-Cellular Leaps; Schizophrenia Drug Shows Less Side Effects-Biotech Movers

    Standard treatments can cause motor side effects and/or weight gain, cardiovascular complications, dyslipidemia, and hyperglycemia.

  • GlobeNewswire2 months ago

    Neuralstem Announces Issuance of Two U.S. Patents

    GERMANTOWN, Md., Sept. 07, 2017-- Neuralstem, Inc., a biopharmaceutical company developing novel treatments for nervous system diseases, today announced that it has been awarded two additional patents ...

  • Capital Cube2 months ago

    ETFs with exposure to Neuralstem, Inc. : August 31, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Neuralstem, Inc. Here are 5 ETFs with the largest exposure to CUR-US. Comparing the performance and risk of Neuralstem, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Neuralstem, Inc. :CUR-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
    Capital Cube2 months ago

    Neuralstem, Inc. :CUR-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017

    Categories: Yahoo FinanceGet free summary analysis Neuralstem, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of Neuralstem, Inc. – Titan Pharmaceuticals, Inc., Cytokinetics, Incorporated, Acorda Therapeutics, Inc., Geron Corporation, Neurocrine Biosciences, Inc., Albany Molecular Research, Inc., BioTime, Inc., Charles River Laboratories International, Inc. and Repligen ... Read more (Read more...)

  • Associated Press2 months ago

    Neuralstem reports 2Q loss

    The Germantown, Maryland-based company said it had a loss of 39 cents per share. The biopharmaceutical company posted revenue of $2,500 in the period. Its adjusted revenue was $3,000. The company's shares ...

  • GlobeNewswire3 months ago

    Neuralstem Reports Second Quarter 2017 Fiscal Results and Provides Clinical and Business Update

    GERMANTOWN, Md., Aug. 08, 2017-- Neuralstem, Inc., a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell technology, reported its financial results ...

  • GlobeNewswire3 months ago

    Neuralstem Awarded $~1MM Grant by NIH to Continue Preclinical Research into the Potential of NSI-189 for Treatment of Diabetic Neuropathy

    GERMANTOWN, Md., Aug. 02, 2017-- Neuralstem, Inc., a biopharmaceutical company developing novel treatments for nervous system diseases, today announced that it has been awarded a Phase 2 Small Business ...

  • GlobeNewswire3 months ago

    Neuralstem Announces Pricing of Public Offering of Common Stock and Warrants

    GERMANTOWN, Md., July 27, 2017-- Neuralstem, Inc., a biopharmaceutical company developing novel treatments for nervous system diseases, today announced the pricing of an underwritten public offering of ...

  • GlobeNewswire3 months ago

    Neuralstem Announces Proposed Public Offering of Common Stock and Warrants

    GERMANTOWN, Md., July 26, 2017-- Neuralstem, Inc., a biopharmaceutical company developing novel treatments for nervous system diseases, today announced it has commenced an underwritten public offering, ...

  • Accesswire3 months ago

    Today's Research Reports on Stocks to Watch: Neuralstem and Flex Pharma

    NEW YORK, NY / ACCESSWIRE / July 26, 2017 / Neuralstem was a big loser in Tuesday trading, dropping as much as 61% in pre-market trading before bouncing back slightly. The company missed its primary endpoint ...

  • Capital Cube4 months ago

    ETFs with exposure to Neuralstem, Inc. : July 4, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Neuralstem, Inc. Here are 5 ETFs with the largest exposure to CUR-US. Comparing the performance and risk of Neuralstem, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Capital Cube5 months ago

    ETFs with exposure to Neuralstem, Inc. : June 2, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Neuralstem, Inc. Here are 5 ETFs with the largest exposure to CUR-US. Comparing the performance and risk of Neuralstem, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Neuralstem, Inc. :CUR-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017
    Capital Cube5 months ago

    Neuralstem, Inc. :CUR-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017

    Categories: Yahoo FinanceGet free summary analysis Neuralstem, Inc. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of Neuralstem, Inc. – Titan Pharmaceuticals, Inc., Cytokinetics, Incorporated, Acorda Therapeutics, Inc., Geron Corporation, Neurocrine Biosciences, Inc., Albany Molecular Research, Inc., Aceto Corporation, BioTime, Inc., Charles River Laboratories International, Inc. ... Read more (Read more...)

  • Capital Cube5 months ago

    ETFs with exposure to Neuralstem, Inc. : May 11, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Neuralstem, Inc. Here are 5 ETFs with the largest exposure to CUR-US. Comparing the performance and risk of Neuralstem, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Accesswire5 months ago

    Today's Research Reports on Stocks to Watch: MannKind and Neuralstem

    NEW YORK, NY / ACCESSWIRE / May 11, 2017 / U.S. markets were relatively quiet Wednesday as investors analyzed the latest batch of corporate earnings. Additionally, President Trump on Wednesday announced ...

  • Associated Press5 months ago

    Neuralstem reports 1Q loss

    The Germantown, Maryland-based company said it had a loss of 68 cents per share. Losses, adjusted for non-recurring costs, were 43 cents per share. The biopharmaceutical company posted revenue of $2,500 ...